LISI Group confirms the sale of its LISI MEDICAL division to SK CAPITAL

Paris, November 3, 2025

LISI Group confirms the sale of its LISI MEDICAL division  to SK CAPITAL

Further to the press release dated October 23, LISI Group confirms the sale of its LISI MEDICAL division (namely LISI MEDICAL – headquartered in Neyron, LISI MEDICAL ORTHOPAEDICS - Caen, LISI MEDICAL FASTENERS - Neyron, and LISI MEDICAL REMMELE - Minneapolis, United States) to SK CAPITAL, a private American investor, on October 31, 2025. LISI MEDICAL has been renamed Precera Medical and has established its headquarters in Minneapolis (United States).

At the same time, LISI Group becomes a partner in Precera Medical's development strategy by acquiring a minority stake of 9.988% in the holding company comprising the entire acquisition by SK CAPITAL, thereby joining the planned development project and the emergence of Precera Medical as a leading CDMO* partner for equipment manufacturers. 

In addition, LISI Group will be able to benefit from an additional payment depending on the terms of SK CAPITAL's exit at the end of its investment.

"This transaction marks the end of an important chapter for LISI Group and the beginning of an exciting new adventure for Precera Medical. I am proud of the growth we have achieved since the division was created in 2010. The long-term foundation we invested in, combined with SK CAPITAL's industrial and financial resources, will enable Precera Medical and its teams to thrive as an independent company supporting the growth of its customers," said Emmanuel Viellard, CEO of LISI Group.

"We are thrilled to be partnering with Dylan Hushka (Chief Executive Officer), the management team, LISI, and the Board of Directors to support the next chapter as Precera Medical. We plan to support continued investment in capacity and expanded capabilities, both organically and through M&A, to support leading OEMs across the most advanced areas of medical technology and accelerate our growth," said Josh Lieberman, Director at SK CAPITAL.

The proceeds from this division’s sale will be used to reduce the debt of LISI Group, which is ambitiously focused on supporting the development of its two strategic activities: aerospace and automotive.   

 

* CMDO: Contract Manufacturing and Development Organization

             

Contact LISI                       

Emmanuel VIELLARD                   Tel.: +33 (0)3 84 57 00 77                

Email: emmanuel.viellard@lisi-group.com           

Website: www.lisi-group.com

 

LISI shares are listed on Euronext, compartment A, and are included in the CAC® AERO & DEF., CAC® All Shares, and CAC® Industrials indices, under ISIN code: FR 0000050353.

Reuters code: GFII.PA / Bloomberg code: FII FP

LISI is a global industrial group with sales of nearly €1.8 billion in 2024 and a workforce of 10,262 people. It specializes in the manufacture of high value-added assembly solutions and components for the aerospace and automotive sectors. As a partner to the world's leading players and driven by long-standing family values, LISI innovates and invests in research and development for the products of tomorrow in order to meet the needs of its customers, particularly in terms of quality, safety, and performance. The LISI Group stands out by relying on two strategic pillars: innovation and operational excellence, while integrating a strong CSR culture. 

For more information, visit: www.lisi-group.com.

Headquarters - 6 rue Juvénal Viellard - CS 70431 GRANDVILLARS - 90008 BELFORT Cedex  

Tel.: +33 (0)3 84 57 00 77 -  www.lisi-group.com  

 Public limited company with capital of €18,615,325.20 - Belfort Trade and Companies Register - Siren 536 820 269                                                          External Public